Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Belgium
In shortMelexis is profitable, generates cash and carries moderate debt, with revenue shrinking (−3.3% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 23.6% | 95/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 18.4% | 94/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 30.7% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 23.5% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.54× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.38× | 90/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.82× | 91/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 10.50× | 86/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 8.27 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 13.4% | 74/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.73× | 54/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 4 | 58/100 |
| Revenue growth volatility | 15.0% | 56/100 |
| Operating margin volatility | 5.0% | 64/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 13.2% | 90/100 |
|---|---|---|
| EPS growth, 3-year average | 9.3% | 71/100 |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 508 | 644 | 836 | 964 | 933 |
| Cost of revenue | 310 | 370 | 461 | 524 | 531 |
| Gross profit | 198 | 274 | 375 | 440 | 401 |
| Research & development | 78 | 78 | 90 | 107 | 110 |
| Operating income | 76 | 148 | 227 | 261 | 220 |
| Interest expense | 5.8 | 7.3 | 12 | 17 | 21 |
| Pre-tax income | 76 | 154 | 238 | 253 | 205 |
| Income tax | 6.6 | 23 | 41 | 44 | 34 |
| Net income | 69 | 131 | 197 | 209 | 171 |
| Diluted EPS | €1.72 | €3.25 | €4.88 | €5.18 | €4.24 |
8.27 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 11, 2025